OVERCOMING BIOLOGICAL BARRIERS TO DRUG DELIVERY
The Mitchell Lab is based in the Department of Bioengineering at the University of Pennsylvania. Our research lies at the interface of biomaterials science, drug delivery, and cellular and molecular bioengineering to fundamentally understand and therapeutically target biological barriers. We apply our research findings and the technologies developed to a range of human health applications, including cancer metastasis, immunotherapy, genome editing, cardiovascular disease, and regenerative medicine. Current research projects include: synthesis of novel biomaterials and nanoparticles for the delivery of nucleic acids (siRNA, miRNA, mRNA, CRISPR-Cas9) for cancer therapy; engineering of immune cells for immunotherapy and vaccines; investigating the influence of biomaterial chemical structure on in vivo transport to target cells and tissues using high-throughput screening platforms; and novel drug delivery technologies for tissue engineering and regenerative medicine.
April 2020 – Congratulations to BE PhD students Rebecca Haley and Sarah Shepherd for being awarded NSF GRFP Fellowships. Their fellowships and research projects are featured by Penn Bioengineering.
A record number of #PennBioengineering current and future graduate students have received @NSFGRFP Fellowships this year. Follow the link to learn more about their current research, conducted at a variety of labs across SEAS & the university: https://t.co/izyMTgVdDR
— Penn Bioengineering (@pennbioeng) May 11, 2020
March 2020 – Congratulations to BE Postdoctoral Fellow Rachel Riley for accepting an Assistant Professor of Biomedical Engineering position at Rowan University. Rachel’s new position is featured by Penn Bioengineering.
Congratulations to #PennBioengineering Postdoc @Rach_Riley27 of the @MJMitchell_Lab who starts a faculty appointment as Assistant Professor of #BiomedicalEngineering at @RowanRCE this fall! @PennEngineers #upenn #newfaculty @RowanUniversity #congrats #BME https://t.co/lvCtaFFzSy
— Penn Bioengineering (@pennbioeng) April 15, 2020
Researchers at @PennEngineers and @PennCancer have found a way to ferry messenger RNA across a T cell’s membrane via a lipid-based nanoparticle, rather than using a modified HIV virus to rewrite the cell’s DNA. https://t.co/nhradal7eN
— Penn (@Penn) February 5, 2020
All in the family… @MJMitchell_Lab Bob Langer @MariaJ_Alonso at #CRS2019 @CRSScience Valencia. Controlled release glory. Think about it! One photo covers the research period 1974 to 2019. pic.twitter.com/kLAIzWeYdA
— Nicholas A. Peppas (@NPeppas) September 5, 2019